Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,616 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort A: placebo Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects

NCT03935568
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PU-AD, Placebo
Drug
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 15, 2026, 8:30 PM EDT
Recruiting Phase 1 Interventional

A Study of LY3971297 in Participants With Heart Failure

NCT07547540
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Interventions
LY3971297, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Detroit, Michigan • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Results available

A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

NCT04279613
View directory record Official record
Conditions
Type I Diabetes
Interventions
NNC0361-0041, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
16
States / cities
Orange, California • San Francisco, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 15, 2026, 8:30 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Belcesiran in Patients With AATLD

NCT04764448
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Belcesiran, Placebo
Drug · Other
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
La Jolla, California • Gainesville, Florida • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1 Interventional

Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis

NCT00818948
View directory record Official record
Conditions
Nephritis, Systemic Lupus Erythematosus
Interventions
AMG 811
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Phoenix, Arizona • Danbury, Connecticut • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 15, 2026, 8:30 PM EDT
Terminated Phase 1 Interventional

A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

NCT01470313
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
PD-0360324, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Anniston, Alabama • Oxford, Alabama • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

NCT01135680
View directory record Official record
Conditions
Drug Toxicity
Interventions
HPN-100, HPN-100 or Placebo, Placebo, Moxifloxacin
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 15, 2026, 8:30 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

NCT07511205
View directory record Official record
Conditions
Healthy Participants, Obesity
Interventions
AZD1043, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers

NCT00990990
View directory record Official record
Conditions
Tuberculosis
Interventions
PNU-100480, Placebo, Linezolid
Drug
Lead sponsor
Sequella, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

NCT02788188
View directory record Official record
Conditions
Middle East Respiratory Syndrome Coronavirus
Interventions
SAB-301, Normal (9%) Saline
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 15, 2026, 8:30 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

NCT06712654
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
Interventions
AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID, AP306 75 mg TID, AP306 100 mg TID, AP306 125 mg TID, Placebo
Drug
Lead sponsor
R1 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Huntsville, Alabama • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience

NCT06072170
View directory record Official record
Conditions
Safety, Pharmacokinetics, Pharmacodynamics
Interventions
Kratom, Placebo
Drug
Lead sponsor
Altasciences Company Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

NCT02459886
View directory record Official record
Conditions
Parkinson's Disease, Healthy
Interventions
BIIB054, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Hallandale, Florida • Oviedo, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 3 Interventional Results available

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

NCT00256854
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole IR 1 mg Placebo, Ropinirole IR 2 mg Placebo, Ropinirole CR 2 mg, Ropinirole CR 3 mg, Ropinirole CR 2 mg Placebo, Ropinirole CR 3 mg Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

NCT04588727
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

NCT04231513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2814, E2814-matched placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
20 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Glendale, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1Phase 2 Interventional

Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty

NCT02982915
View directory record Official record
Conditions
Aging Frailty
Interventions
Longeveron Mesenchymal Stem Cells (LMSCs), Fluzone High Dose Vaccine
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
6
States / cities
Coral Gables, Florida • Fort Myers, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers

NCT04527718
View directory record Official record
Conditions
Healthy
Interventions
Placebo, 611
Drug
Lead sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

NCT02293148
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety and PK of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults

NCT03046550
View directory record Official record
Conditions
Healthy
Interventions
NTM-1634, Placebo
Drug
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 48 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions

NCT06192589
View directory record Official record
Conditions
Cannabidiol, Drug Induced Liver Injury, Drug Interaction
Interventions
Cannabidiol, Placebo, Citalopram, Morphine
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 15, 2026, 8:30 PM EDT
Recruiting Phase 3 Interventional

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT07743463
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management
Interventions
ASC30 tablets A1, Placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years and older
Enrollment
3,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 15, 2026, 8:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-235 in Healthy Subjects

NCT05246878
View directory record Official record
Conditions
SARS CoV 2 Infection
Interventions
EDP-235, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 15, 2026, 8:30 PM EDT